Patents Examined by Rebecca Anderson
-
Patent number: 9783506Abstract: The present invention provides a process for the large scale production of 1H-[1,2,3]triazole of formula (I) and its intermediate 1-benzyl-1H-[1,2,3]triazole of formula (II) by using benzyl azide and vinyl acetate as starting materials. This process is economical, environment friendly and safer by avoiding use of special equipment.Type: GrantFiled: January 27, 2014Date of Patent: October 10, 2017Assignee: SUVEN LIFE SCIENCES LIMITEDInventors: Veera Reddy Arava, Sashibhushan Malreddy, Chalapathi Lagupudi, Venkateswarlu Jasti
-
Patent number: 9776988Abstract: A compound represented by the general Formula (I), wherein hydrogen atoms shown as attached to pyrazole and benzimidazole rings are attached to one of nitrogen atoms of the pyrazole or benzimidazole ring, respectively; R1 represents —X-Q-P, wherein X is absent or represents —CH2—, —C(O)—, or —C(O)NH—(CH2)k—, wherein k is 0, 1 or 2; Q is selected from the group consisting of Q1, Q2, Q3, Q4 and Q5; P is absent or represents straight- or branched-chain C1-C3 alkyl, —(CH2)l—NR2R3, or —(CH2)m—C(O)—NR2R3, wherein l and m independently of each other represent 0, 1 or 2, with the proviso that when B in Q1 represents oxygen atom, then P is absent; and R2 and R3 independently represent C1 or C2 alkyl, or R2 and R3 together with nitrogen atom to which they are both attached form a 6-membered saturated heterocyclic ring, wherein one of carbon atoms can be replaced with oxygen, —NH— or —N(C1-C2)alkyl-; and acid addition salts thereof. The compound can be useful in the treatment of cancer diseases.Type: GrantFiled: March 7, 2014Date of Patent: October 3, 2017Assignee: Celon Pharma S.A.Inventors: Daria Zdzalik, Joanna Lipner, Maciej Wieczorek, Karolina Dzwonek, Abdellah Yamani, Krzysztof Dubiel, Monika Lamparska-Przybysz, Paulina Grygielewicz, Aleksandra Stanczak
-
Patent number: 9771358Abstract: Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases.Type: GrantFiled: March 27, 2015Date of Patent: September 26, 2017Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Yingjun Zhang, Qingyun Ren, Xinchang Liu, Siegfried Goldmann
-
Patent number: 9765087Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: April 4, 2014Date of Patent: September 19, 2017Assignee: ENANTA PHARMACEUTICALS, INC.Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Hui Cao, Lu Ying, Xuri Gao, Bin Wang, Yat Sun Or
-
Patent number: 9765060Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (J), or pharmaceutically acceptable salts thereof, in which A, n, m, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms. The present disclosure further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms.Type: GrantFiled: June 23, 2015Date of Patent: September 19, 2017Assignee: GILEAD SCIENCES, INC.Inventors: Jerry Evarts, Joshua Kaplan, Musong Kim, Devan Naduthambi, Leena Patel, Stephane Perreault, Gary Phillips, Lafe J. Purvis, II, Kirk L. Stevens, Jennifer A. Treiberg
-
Patent number: 9765066Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1 and/or HDAC2. Such diseases include cancer, sickle-cell anemia, beta-thalassemia, and HIV.Type: GrantFiled: July 19, 2016Date of Patent: September 19, 2017Assignee: REGENACY PHARMACEUTICALS, LLCInventors: John H. van Duzer, Ralph Mazitschek
-
Patent number: 9765063Abstract: Amido compounds are disclosed that have a formula represented by the following: and wherein Cy1, Cy2, n1, n2, R1a, R1b, R2, R3, R4, R5, and R6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.Type: GrantFiled: September 10, 2012Date of Patent: September 19, 2017Assignees: New York University, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Dan Littman, Jun R. Huh, Ruili Huang, Wenwei Huang, Erika E. Englund
-
Patent number: 9758480Abstract: A compound represented by formula (1) (in the formula: ring-D represents a three- to eight-membered hydrocarbon ring; Ra represents an optionally substituted amino C1-6 alkyl group or the like; Rb1 and Rb2 each independently represent a hydrogen atom, a halogen atom, or the like; Rc represents an optionally substituted C6-10 aryl group or the like; Rd represents a hydrogen atom or the like; and ring-Q represents a (hetero)aryl group or the like which may be substituted with a carboxyl group or the like) or a pharmaceutically acceptable salt thereof exhibits an excellent FXIa inhibitory activity, and is useful as a therapeutic agent against thrombosis or the like.Type: GrantFiled: July 18, 2013Date of Patent: September 12, 2017Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Yohei Ikuma, Nobuhisa Fukuda, Masato Iwata, Hidenori Kimura, Kuniko Suzuki
-
Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
Patent number: 9758491Abstract: This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions containing such molecules, and processes of using such pesticidal compositions against such pests. These pesticidal compositions may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides. This document discloses molecules having the following formula (“Formula One”).Type: GrantFiled: August 25, 2016Date of Patent: September 12, 2017Assignee: Dow AgroSciences LLCInventors: Gary D. Crouse, Lindsey G Horty, Erich W. Baum, Thomas C. Sparks -
Patent number: 9758495Abstract: The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor of Formula (I).Type: GrantFiled: March 13, 2014Date of Patent: September 12, 2017Assignee: Amgen Inc.Inventors: Ana Gonzalez Buenrostro, Yihong Li, Julio C. Medina, Steven H. Olson
-
Patent number: 9751892Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: GrantFiled: September 17, 2015Date of Patent: September 5, 2017Assignee: Nimbus Iris, Inc.Inventors: Jeremy Robert Greenwood, Geraldine C. Harriman, Rosana Kapeller-Libermann, Craig E. Masse, Shaughnessy Robinson, Donna L. Romero, Mee Shelley, Ronald T. Wester
-
Patent number: 9738638Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.Type: GrantFiled: September 8, 2015Date of Patent: August 22, 2017Assignee: Samumed, LLCInventors: Sunil Kumar KC, David Mark Wallace, Jianguo Cao, Chandramouli Chiruta, John Hood
-
Patent number: 9738628Abstract: In one aspect, the invention relates to substituted 1H-benzo[d][1,2,3]triazol-1-ol analgoues, derivatives thereof, and related compound; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders, e.g. various tumors and cancers, associated with ?-catenin/Tcf protein-protein interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: February 5, 2016Date of Patent: August 22, 2017Assignee: University of Utah Research FoundationInventors: Haitao Ji, Binxun Yu, Min Zhang, Wenxing Guo
-
Patent number: 9730913Abstract: Inhibitors of beta lactamases and their use in treating bacterial infections are disclosed.Type: GrantFiled: October 12, 2012Date of Patent: August 15, 2017Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Ernesto Freire, Rogelio Siles, Patrick C. Ross
-
Patent number: 9732095Abstract: The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors, wherein A, Y, Z, X1, X2, R1, R3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.Type: GrantFiled: January 12, 2015Date of Patent: August 15, 2017Assignee: Aurigene Discovery Technologies LimitedInventors: Venkateshwar Rao Gummadi, Susanta Samajdar
-
Patent number: 9732094Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation.Type: GrantFiled: May 8, 2014Date of Patent: August 15, 2017Assignee: Merck Patent GmbHInventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
-
Patent number: 9725451Abstract: The present invention provides novel derivative of ?-lactam antibiotics, such as meropenem. The inventive compounds include compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. Also provided are particles (e.g., nanoparticles) and pharmaceutical compositions thereof that are mucus penetrating. The inventive particles and pharmaceutical compositions may be useful in delivering an inventive compound to the respiratory tract of a subject. The invention further provides methods of using and kits including the inventive compounds, particles thereof, and/or pharmaceutical compositions thereof for treating and/or preventing a pulmonary disease (e.g., a respiratory tract infection).Type: GrantFiled: March 14, 2014Date of Patent: August 8, 2017Assignee: Kala Pharmaceuticals, Inc.Inventors: Winston Zapanta Ong, Pawel Wojciech Nowak, Jinsoo Kim, Elizabeth M Enlow, James Bourassa, Yen Cu, Alexey Popov, Hongming Chen
-
Patent number: 9725463Abstract: The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium release-activated calcium (CRAC) channel. The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium release-activated calcium (CRAC) channel modulators. wherein, ring D is Formula (a) or Formula (b): A and B, which may be same or different, are independently CR3 or N; Y is CR3 or N; L is selected from —NR2C(O)—, —C(O)NR2— and —NR2CRaRb—; Ra and Rb are independently hydrogen, halogen or substituted or unsubstituted alkyl; ring E is selected from the Formula (i) to (vii).Type: GrantFiled: June 20, 2014Date of Patent: August 8, 2017Assignee: LUPIN LIMITEDInventors: Nageswara Rao Irlapati, Nilesh Raghunath Khedkar, Ravindra Babanrao Jape, Rahul Shripad Nandurdikar, Zubair Abdul Wajid Shaikh, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9725461Abstract: The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.Type: GrantFiled: November 12, 2014Date of Patent: August 8, 2017Assignee: Curis, Inc.Inventors: Xiong Cai, Haixaio Zhai, Chengjung Lai, Changgeng Qian
-
Patent number: 9717736Abstract: There is provided a compound of formula I: or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.Type: GrantFiled: June 8, 2015Date of Patent: August 1, 2017Assignee: Kudos Pharmaceuticals LimitedInventors: Heather Mary Ellen Duggan, Frederic Georges Marie Leroux, Karine Fabienne Malagu, Niall Morrison Barr Martin, Keith Menear, Graeme Cameron Murray Smith